Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI South Africa ETF (EZA) vs McKesson Corporation (MCK) Price & Performance

iShares MSCI South Africa ETFTrade
McKesson CorporationTrade

Price performance (Past 24H)

Key statistics

iShares MSCI South Africa ETF vs McKesson Corporation — how do they compare? iShares MSCI South Africa ETF trades at $62.57 (market cap $466.20M), while McKesson Corporation trades at $921.5 (market cap $106.14B). The key difference: McKesson Corporation is far larger — about 227.7× iShares MSCI South Africa ETF's market cap, and McKesson Corporation pays a 0.41% dividend while iShares MSCI South Africa ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Africa ETF for 70 Days and McKesson Corporation for 74 Days on average.

EZAMCK
Market Cap
$466.20M$106.14B
Volume
152,369794,405
Sector
Broad Market / FactorHealth
52-Week High
$81.60$995.69
52-Week Low
$60.43$725.17
Typical Hold Time
70 Days74 Days
Enterprise Value
—$112.67B
Dividend Yield
—0.41%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI South Africa ETF

EZA trades at $62.29, down 2.15% today, with a bearish technical signal driven by moving averages. The ETF's portfolio faces headwinds from global reflation impacting its heavy exposure to South African gold, banking, and platinum group metals. Key oscillators like the 6-day and 12-day relative strength index indicate oversold conditions, suggesting potential for a near-term bounce, but the average directional index signals a strong downtrend.

The outlook is cautious due to macroeconomic pressures on constituent companies, with risks from higher capital costs and commodity price volatility. Investment opportunity hinges on a reversal in global yield curves and commodity markets, but current sentiment remains negative amid sell-side dominance and lack of positive fundamental catalysts.

McKesson Corporation

McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.

Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EZA
100% Buy0% Sell
Avg holding period · 70 Days
MCK
40% Buy60% Sell
Avg holding period · 74 Days

Top news

Latest headlines on both assets

About iShares MSCI South Africa ETF

EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.

Read more on EZA →

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK →